{"filing":{"accession_number":"0001193125-26-248680","cik":"0001858848","ticker":"TNYA","company_name":"Tenaya Therapeutics, Inc.","form":"8-K","filing_date":"2026-05-29","report_date":null,"primary_document":"tnya-20260527.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1858848/000119312526248680/tnya-20260527.htm"},"events":[{"id":2150,"run_id":1867,"accession_number":"0001193125-26-248680","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Tenaya Therapeutics held its Annual Meeting of Stockholders on May 27, 2026, with shareholders voting on three proposals: election of three Class II directors (Amy Burroughs, Karah Parschauer, and Catherine Stehman-Breen), ratification of Deloitte \u0026 Touche LLP as independent auditor, and approval of the amended 2021 Equity Incentive Plan. All three proposals passed with substantial majorities.","company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","filing_date":"2026-05-29","items":[{"id":2742,"accession_number":"0001193125-26-248680","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Tenaya Therapeutics' annual meeting held May 27, 2026. The filing reports results for three proposals: election of Class II directors (Amy Burroughs, Karah Parschauer, and Catherine Stehman-Breen), ratification of Deloitte \u0026 Touche LLP as independent auditor, and approval of the amended 2021 Equity Incentive Plan. All three proposals passed with substantial majorities, making this a material disclosure of shareholder actions that affects governance and compensation arrangements.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:15:26.053208+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":2151,"run_id":1867,"accession_number":"0001193125-26-248680","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"The Company's 2021 Equity Incentive Plan was amended and restated, effective upon stockholder approval at the May 27, 2026 Annual Meeting, including a one-time increase of approximately 3% of outstanding shares (6,509,966 shares) to the share reserve, removal of the annual 4 million share cap on the evergreen provision while maintaining a 4% annual increase, and limitations on incentive stock options.","company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","filing_date":"2026-05-29","items":[{"id":2741,"accession_number":"0001193125-26-248680","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure describes an amendment and restatement of the Company's 2021 Equity Incentive Plan, effective upon stockholder approval at the Annual Meeting on May 27, 2026. The amendments include a one-time increase of approximately 3% of outstanding shares (6,509,966 shares) to the share reserve, removal of the annual 4 million share cap on the evergreen provision while maintaining a 4% annual increase, and limitations on incentive stock options. This is a material compensatory arrangement amendment affecting equity grants and incentive compensation for officers and directors, squarely within the scope of Item 5.02(e).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:15:26.053208+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2741,"accession_number":"0001193125-26-248680","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure describes an amendment and restatement of the Company's 2021 Equity Incentive Plan, effective upon stockholder approval at the Annual Meeting on May 27, 2026. The amendments include a one-time increase of approximately 3% of outstanding shares (6,509,966 shares) to the share reserve, removal of the annual 4 million share cap on the evergreen provision while maintaining a 4% annual increase, and limitations on incentive stock options. This is a material compensatory arrangement amendment affecting equity grants and incentive compensation for officers and directors, squarely within the scope of Item 5.02(e).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:15:26.053208+00:00","company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","filing_date":"2026-05-29"},{"id":2742,"accession_number":"0001193125-26-248680","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Tenaya Therapeutics' annual meeting held May 27, 2026. The filing reports results for three proposals: election of Class II directors (Amy Burroughs, Karah Parschauer, and Catherine Stehman-Breen), ratification of Deloitte \u0026 Touche LLP as independent auditor, and approval of the amended 2021 Equity Incentive Plan. All three proposals passed with substantial majorities, making this a material disclosure of shareholder actions that affects governance and compensation arrangements.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:15:26.053208+00:00","company_name":"Tenaya Therapeutics, Inc.","ticker":"TNYA","filing_date":"2026-05-29"}]}